Charles University in Prague-ko ikertzaileekin lankidetzan egindako argitalpenak (31)

2024

  1. Simulation to become a better neurosurgeon. An international prospective controlled trial: The Passion study

    Brain and Spine, Vol. 4

2023

  1. Disability accrual in primary and secondary progressive multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 94, Núm. 9, pp. 707-717

  2. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial

    Journal of neurology, neurosurgery, and psychiatry, Vol. 94, Núm. 12, pp. 1004-1011

  3. In-hospital and 6-month outcomes in patients with COVID-19 supported with extracorporeal membrane oxygenation (EuroECMO-COVID): a multicentre, prospective observational study

    The Lancet Respiratory Medicine, Vol. 11, Núm. 2, pp. 151-162

2022

  1. Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study

    Neurology, Vol. 98, Núm. 24, pp. E2401-E2412

  2. Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180

    Computer methods and programs in biomedicine

2021

  1. Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis

    Multiple Sclerosis Journal, Vol. 27, Núm. 5, pp. 755-766

2020

  1. Sequential targeted exome sequencing of 1001 patients affected by unexplained limb-girdle weakness

    Genetics in Medicine, Vol. 22, Núm. 9, pp. 1478-1488

2019

  1. Clinical and genetic characteristics of late-onset Huntington's disease

    Parkinsonism and Related Disorders, Vol. 61, pp. 101-105

  2. Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 10, pp. 1405-1411

2018

  1. Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes the TRIGR randomized clinical trial

    JAMA - Journal of the American Medical Association, Vol. 319, Núm. 1, pp. 38-48

  2. Integrative analysis of transcriptomics and clinical data uncovers the tumor-suppressive activity of MITF in prostate cancer

    Cell Death and Disease, Vol. 9, Núm. 10

  3. Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod

    Multiple Sclerosis and Related Disorders, Vol. 19, pp. 105-108

  4. Reduced Cancer Incidence in Huntington's Disease: Analysis in the Registry Study

    Journal of Huntington's Disease, Vol. 7, Núm. 3, pp. 209-222

2017

  1. Cognitive decline in Huntington's disease expansion gene carriers

    Cortex, Vol. 95, pp. 51-62

2016

  1. Defining secondary progressive multiple sclerosis

    Brain, Vol. 139, Núm. 9, pp. 2395-2405

  2. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

2015

  1. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis

    JAMA Neurology, Vol. 72, Núm. 4, pp. 405-413

  2. Defining reliable disability outcomes in multiple sclerosis

    Brain, Vol. 138, Núm. 11, pp. 3287-3298